Promedigen Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $1.4M

  • Investors
  • 3

Promedigen General Information

Description

Operator of a biotechnology company intended to treat cancer and neurodegenerative disorders. The company specializes in providing customized modified protein technology that helps in the production of abnormally modified proteins that are associated with a variety of serious diseases, enabling doctors to treat cancer, dementia, and various other diseases effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Munji-ro, Yuseong-gu
  • 113-115, Daejeon, Munji-dong
  • Daejeon, 27216
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Munji-ro, Yuseong-gu
  • 113-115, Daejeon, Munji-dong
  • Daejeon, 27216
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Promedigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series B) 01-Dec-2024 $1.4M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 01-Nov-2020 Completed Pre-Clinical Trials
To view Promedigen’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Promedigen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Promedigen Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Sugentech Corporation Minority
Company K Partners Venture Capital Minority
DSC Investment Venture Capital Minority
To view Promedigen’s complete investors history, request access »

Promedigen FAQs

  • When was Promedigen founded?

    Promedigen was founded in 2019.

  • Where is Promedigen headquartered?

    Promedigen is headquartered in Daejeon, South Korea.

  • What is the size of Promedigen?

    Promedigen has 12 total employees.

  • What industry is Promedigen in?

    Promedigen’s primary industry is Drug Discovery.

  • Is Promedigen a private or public company?

    Promedigen is a Private company.

  • What is Promedigen’s current revenue?

    The current revenue for Promedigen is .

  • How much funding has Promedigen raised over time?

    Promedigen has raised $1.4M.

  • Who are Promedigen’s investors?

    Sugentech, Company K Partners, and DSC Investment have invested in Promedigen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process